GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Long-Term Debt

Noile-Immune Biotech (TSE:4893) Long-Term Debt : 円0.0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Long-Term Debt?

Noile-Immune Biotech's Long-Term Debt for the quarter that ended in Mar. 2024 was 円0.0 Mil.


Noile-Immune Biotech Long-Term Debt Historical Data

The historical data trend for Noile-Immune Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Long-Term Debt Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Long-Term Debt
- - - -

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only - - - - -

Noile-Immune Biotech  (TSE:4893) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Noile-Immune Biotech Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines